Keros Therapeutics
Keros is dedicated to discovery and development of novel therapeutics for hematological and musculoskeletal disorders.
Keros is dedicated to discovery and development of novel therapeutics for hematological and musculoskeletal disorders.
Keros Therapeutics is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in the United States. The company is dedicated to the discovery and development of novel therapeutics for hematological and musculoskeletal disorders, focusing on patients with rare disorders and high unmet medical need. Keros aims to bring novel treatments to these patient populations. The company recently received a significant $140.00M Post-IPO Equity investment on 03 January 2024. This investment underscores investor confidence in Keros' potential to address critical medical needs in the biotechnology, health care, and pharmaceutical industries. With this funding, Keros is well-positioned to advance its research and development efforts and further its journey towards bringing new therapies to the market.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $140.00M | - | 03 Jan 2024 | |
| Post-IPO Equity | $149.50M | - | 13 Nov 2020 | |
| Series C | $56.00M | 9 |
|
04 Mar 2020 |
| Series B | $23.00M | 1 | Medison | 08 Jan 2019 |
| Series A | $11.00M | - | 09 Nov 2017 |
No recent news or press coverage available for Keros Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
